We served as lead counsel representing the former owners of a multi-state retail pharmacy chain in connection with a Department of Justice (DOJ) investigation regarding alleged violations of the False Claims Act (FCA) resulting from inaccurate reporting of usual and customary pricing of generic drugs. The case resulted in declination by DOJ and dismissal of the underlying qui tam lawsuit after the filing of a motion to dismiss under the FCA’s first-to-file rule. Reported case: U.S. ex rel. Phillis v. Stephen L. LaFrance Holdings, 2018 WL 4839057 (N.D. Okla. Oct. 4, 2018).
Representation of Retail Pharmacy Owners: U.S. ex rel. Phillips v. Stephen L. LaFrance Holdings, Inc. (N.D. Okla.)
You Also May Be Interested In:
Successful Defense of National Home Healthcare Provider in Appealing $18 Million Extrapolated Overpayment Resulting from UPIC Audit
We successfully defended a national home healthcare provider in appealing an $18 million extrapolated overpayment resulting from a UPIC audit.
We represented a global for-profit health insurance company with more than 20 million members in False Claims Act (FCA) litigation in federal court in the Northern District of Illinois.
Representation of ED company and other defendants in qui tam lawsuit alleging that ED provider’s violation of licensure laws caused submission of false claims and that defendants fraudulently billed services as performed by physicians even though patients were seen only by nurse practitioners. We obtained dismissal of the licensure claims and received summary judgment as to the upcoding claims. U.S. ex rel. Taylor v. Boyko, 2020 WL 520933 (S.D. W. Va. Jan. 31, 2020); U.S. ex rel. Taylor v. Perni, 2020 WL 2499544 (S.D. W. Va. May 14, 2020).